Cure My Disease

Don't miss your cure!

 Log in / Sign up

New gel shows promise for eczema relief

NCT ID NCT06024499

Completed Symptom relief Sponsor: Shaperon Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tested a gel called HY209 on 210 adults with mild to moderate atopic dermatitis (eczema). The study compared different strengths of the gel to a placebo to see if it could reduce skin redness, itching, and rash. Results will show whether the gel is safe and effective enough to move to larger studies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
HY209 gel (0.5%, 1%, 2%, or 4%)
What this could lead to
If successful, this gel could offer a new topical option to ease eczema symptoms like redness and itching.
What could go wrong
This is an early-phase trial with only 210 people. The gel may not work better than placebo, and side effects are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atopic eczema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATOPIC DERMATITIS ATOPIC DERMATITIS (ECZEMA) ATOPIC DERMATITIS OF SCALP

Contacts and locations

Locations

  • Cahaba Dermatology Skin Health Center

    Birmingham, Alabama, 35244, United States

  • Continental Clinical Solutions, LLC

    Towson, Maryland, 21204, United States

  • Gachon University Gil Medical Center

    Seoul, South Korea

  • L.A. Universal Research Center, Inc.

    Los Angeles, California, 90057, United States

  • RAOOF MD Dermatology

    Encino, California, 16133, United States

  • Revival Research Institute, LLC

    Southfield, Michigan, 19505, United States

  • Sadick Dermatology

    New York, New York, 10075, United States

  • Seoul National University Bundang Hospital

    Seoul, South Korea

  • Seoul National University Hospital

    Seoul, South Korea

  • Severance Hospital, Yonsei University Health System

    Seoul, South Korea

  • University of Pittsburgh Medical Center

    Pittsburgh, Pennsylvania, 15213, United States

  • Zenith Research Inc.

    Los Angeles, California, 90212, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.